ClinicalTrials.gg
CompletedNCT07223060Updated Dec 11, 2025

Efficacy of Toothpaste Containing 0.454% Stannous Fluoride as Compared to a Regular Fluoride Toothpaste Containing 0.76% Sodium Monofluorophosphate in Controlling Supragingival Calculus Formation Over a 12-week Period.

A Phase 2/3 interventional study of 0.454% stannous fluoride and 0.76% sodium monofluorophosphate in Calculus, Dental, sponsored by Colgate Palmolive. Completed at 1 site in Thailand. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Colgate Palmolive · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2017, 9 years 1 month ago, and no results have been posted to the registry.
  • Registered 8 years 5 months after the study started (first participant enrolled May 2017, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate the comparative clinical efficacy of a test toothpaste containing 0.454% stannous fluoride as compared to a regular fluoride toothpaste containing 0.76% sodium monofluorophosphate in controlling supragingival calculus formation over a 12-week period.

02

Conditions studied

  • Calculus, Dental
03

In context

Lead sponsor

Colgate Palmolive is the lead sponsor of 120 studies on the registry; 14 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 2 (6%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were required to sign an form
  • Subjects had to be in general good health
  • Male and female adults between the ages of 18-70 (inclusive)
  • Six (6) scoreable mandibular anterior teeth free of large restorations or dental prosthetic crowns
  • Subjects were required to possess a Volpe-Manhold Calculus Index of at least 7.0
  • Subjects had to be able to participate for the full duration (20 weeks) of the study

Exclusion criteria

Exclusion Criteria:

  • Presence of orthodontic appliances or removable prosthesis at the lower jaw or more than one mandibular anterior tooth with a prosthetic crown or veneer
  • Tumor(s) or significant pathology of the soft or hard tissues of the oral cavity
  • Moderate or advanced periodontal disease
  • Five or more carious lesions requiring immediate care
  • Use of antibiotics or any time during one month prior to entry into the study
  • Participation in any other clinical study or panel test
  • Pregnant or breast feeding women
  • History of allergies to dentifrice and personal care ingredients
  • Allergies to dentifrice products
  • Medical reasons that prohibit eating or drinking for 4 hours prior to clinical facility visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Test 1 toothpaste

    Drug: 0.454% stannous fluoride

  • Active comparator
    Test 2 toothpaste

    Drug: 0.76% sodium monofluorophosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Supragingival calculus formation via Volpe-Manhold Calculus Index

    index for comparing the amount of dental calculus

    Time frame: baseline and 12 week measurement

07

Study locations

1 site
  • M U International Oral Science Research, Ltd.
    Bangkok, Bangkok 10250, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Oct 2017, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
May 17, 2017
Primary completionActual
Oct 6, 2017
CompletionActual
Oct 6, 2017
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223060
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
May 17, 2017
Primary completion
Oct 6, 2017
Completion
Oct 6, 2017
Last update
Dec 11, 2025

Study contacts

Dutmanee Seriwatanachai
principal investigator · Mahidol University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion